Transition Therapeutics Shares Add 2%; Doses First Patient in Phase 2 Study in …

Transition Therapeutics Shares Add 2%; Doses First Patient in Phase 2 Study in …

… higher 2.5% on Tuesday after the company said it has dosed the first patient in a phase 2 study of TT701 in improving the symptoms of androgen deficiency — sexual symptoms, fatigue/low vitality, and physical dysfunction — in men with prostate cancer.

(Visited 3 times, 1 visits today)
2
Like
Save

Comments

Write a comment